Apellis Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Apellis Pharmaceuticals's earnings have been declining at an average annual rate of -16.9%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 47.6% per year.
Key information
-16.9%
Earnings growth rate
-3.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 47.6% |
| Return on equity | -156.5% |
| Net Margin | -79.6% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Apellis Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 524 | -417 | 528 | 0 |
| 31 Dec 23 | 397 | -529 | 501 | 0 |
| 30 Sep 23 | 273 | -606 | 443 | 387 |
| 30 Jun 23 | 185 | -657 | 376 | 387 |
| 31 Mar 23 | 106 | -691 | 328 | 0 |
| 31 Dec 22 | 75 | -652 | 277 | 0 |
| 30 Sep 22 | 113 | -634 | 234 | 346 |
| 30 Jun 22 | 97 | -638 | 202 | 296 |
| 31 Mar 22 | 81 | -702 | 187 | 346 |
| 31 Dec 21 | 67 | -746 | 177 | 0 |
| 30 Sep 21 | 256 | -520 | 180 | 21 |
| 30 Jun 21 | 251 | -460 | 171 | 71 |
| 31 Mar 21 | 251 | -360 | 150 | 21 |
| 31 Dec 20 | 251 | -345 | 139 | 300 |
| 30 Sep 20 | 1 | -536 | 122 | -142 |
| 30 Jun 20 | 0 | -470 | 104 | -91 |
| 31 Mar 20 | 0 | -423 | 88 | -40 |
| 31 Dec 19 | 0 | -305 | 67 | 11 |
| 30 Sep 19 | 0 | -228 | 46 | 173 |
| 30 Jun 19 | 0 | -194 | 34 | 152 |
| 31 Mar 19 | 0 | -156 | 27 | 128 |
| 31 Dec 18 | 0 | -128 | 23 | 0 |
| 30 Sep 18 | 0 | -109 | 21 | 88 |
| 30 Jun 18 | 0 | -85 | 17 | 68 |
| 31 Mar 18 | 0 | -64 | 13 | 50 |
| 31 Dec 17 | 0 | -51 | 10 | 40 |
| 30 Sep 17 | 0 | -39 | 7 | 33 |
| 30 Jun 17 | 0 | -35 | 6 | 29 |
| 31 Mar 17 | 0 | -30 | 5 | 25 |
| 31 Dec 16 | 0 | -27 | 4 | 23 |
| 30 Sep 16 | 0 | -29 | 6 | 21 |
| 30 Jun 16 | 0 | -53 | 7 | 19 |
| 31 Mar 16 | 0 | -50 | 7 | 16 |
| 31 Dec 15 | 0 | -47 | 6 | 14 |
| 30 Sep 15 | 0 | -41 | 4 | 12 |
| 30 Jun 15 | 0 | -12 | 4 | 10 |
| 31 Mar 15 | 0 | -12 | 3 | 9 |
| 31 Dec 14 | 0 | -11 | 3 | 8 |
Quality Earnings: 1JK is currently unprofitable.
Growing Profit Margin: 1JK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1JK is unprofitable, and losses have increased over the past 5 years at a rate of 16.9% per year.
Accelerating Growth: Unable to compare 1JK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1JK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: 1JK has a negative Return on Equity (-156.47%), as it is currently unprofitable.